Drug Type Small molecule drug |
Synonyms CCR5/CCR2 antagonist, Cenicriviroc, Cenicriviroc mesylate (USAN) + [3] |
Target |
Action antagonists |
Mechanism CCR2 antagonists(C-C chemokine receptor type 2 antagonists), CCR5 antagonists(C-C chemokine receptor type 5 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC42H56N4O7S2 |
InChIKeyIXPBPUPDRDCRSY-YLZLUMLXSA-N |
CAS Registry497223-28-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09879 | Cenicriviroc mesylate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fibrosis, Liver | Phase 3 | United States | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Australia | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Austria | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Belgium | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Brazil | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Canada | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Chile | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | France | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Germany | 05 Apr 2017 | |
Fibrosis, Liver | Phase 3 | Greece | 05 Apr 2017 |
Phase 3 | 1,971 | tngpakfhmy(ctvqeozxcj) = hzoqmlsqhl uebtcazzlr (maekmbznkt ) | - | 10 Jul 2023 | |||
tngpakfhmy(ctvqeozxcj) = splhlhyvbt uebtcazzlr (maekmbznkt ) | |||||||
Phase 3 | 1,971 | (Standard of Care + Infliximab) | gpyenbozbz = jgpyvyenwx hwvuvbgolo (tgqdmaxliw, iiqhfkewwv - ifvnrbpirn) View more | - | 21 Apr 2023 | ||
Placebo+Infliximab (Standard of Care + Infliximab Matching Placebo) | gpyenbozbz = gqnunqyuvb hwvuvbgolo (tgqdmaxliw, wyrzckujtr - hpnblywxrn) View more | ||||||
Phase 3 | 1,778 | eypvjbknwd(takecschbv): odds ratio = 0.84 (95% CI, 0.63 - 1.1) | Negative | 13 Apr 2023 | |||
Placebo | |||||||
Phase 3 | 1,778 | Placebo (Placebo) | xmesxouevr = ghchqegpeg mpbfvlvogr (kjjvrfemgg, svqmtqpdhe - kmwzawvmht) View more | - | 10 Mar 2022 | ||
(Cenicriviroc 150 mg) | xmesxouevr = uyujtppclp mpbfvlvogr (kjjvrfemgg, jwqcnqknwp - fbjgiywhtk) View more | ||||||
Phase 2 | 167 | mtwhlgvqft = fdwpazkkmt ttlbjpcivy (ctishsdbbi, eafdvfyoig - ldgckfmyql) View more | - | 02 Feb 2022 | |||
Not Applicable | 761 | (经外周静脉穿刺中心静脉置管 PICC) | wdebqqnzrr(uguljxgqqf) = lbrcdkpyvv oldrshmufi (yvorgalppk ) View more | - | 25 Sep 2021 | ||
Phase 2 | 20 | xruuguefgm(itbrfjisdo) = vcxduxyojz cmttokwuum (rxlzrznoix ) View more | Positive | 22 Dec 2020 | |||
Phase 2 | 20 | bbwtrhdcgl(fhjlfbiipa) = wweetoqucb gdfieaopbl (ugazrnhaur, azwmicinjl - bbuslnwcwi) View more | - | 20 Aug 2020 | |||
Phase 2 | 45 | (Cenicriviroc 150 mg) | xzzmjpovwi(tfonzmqpmc) = fgahajpfls vsqmpyqpjj (fuztolbjfx, 0.661) View more | - | 11 Oct 2019 | ||
Placebo (Placebo) | xzzmjpovwi(tfonzmqpmc) = qnbwfkzsrj vsqmpyqpjj (fuztolbjfx, 0.595) View more | ||||||
Phase 2 | Nonalcoholic Steatohepatitis high-sensitivity C-reactive protein | fibrinogen | interleukin (IL)-6 ... View more | 289 | dtkdtmdflq(otflqygzlv) = adverse events were comparable for CVC and placebo; no deaths occurred jlzhgynxjt (rzqdtqcdna ) | Positive | 19 Sep 2019 | ||
Placebo |